CD45RO (T-Cell Marker) Ab-1 (Clone UCHL-1)

Mouse Monoclonal Antibody

Cat. #MS-112-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 100μg/ml) (Purified Ab with BSA and Azide)
Cat. #MS-112-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)
Cat. #MS-112-R7 (7.0ml) (Ready-to-Use for Immunohistochemistry)
Cat. #MS-112-RQ (12.0ml) (Ready-to-use for Immunohistochemistry)
Cat. #MS-112-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective December 6, 2011

Description: CD45RO (an isoform of leukocyte common antigen) is expressed on most thymocytes, monocytes, macrophages and granulocytes. It is not expressed on normal B lymphocytes. Intrathymic T cell maturation progresses from CD45RA+/CD45RO- to CD45RA+/CD45RO+; while peripheral T cell maturation progresses from CD45RA+/CD45RO- to CD45RA-/CD45RO+.

Comments: Ab-1 reacts with mature activated T-cells, most thymocytes, and a sub-population of resting T-cells within both CD4 and CD8 subsets. Shows no reactivity with normal B or natural killer cells, but reacts with granulocytes and monocytes. It rarely stains B cell lymphomas.

Mol. Wt. of Antigen: 180kDa

Epitope: Not determined


Clone Designation: UCHL-1 (Workshop IV)

Ig Isotype / Light Chain: IgG2a / κ

Immunogen:
Interleukin-2-dependent human T lymphocytes

Applications and Suggested Dilutions:
- Flow Cytometry
- Immunohistology (Formalin/paraffin)

Use Ab 1:200-400 for 20 min at RT using UltraVision LP Detection Systems
  * [No special pretreatment is required for immunohistochemistry of formalin/paraffin tissues]

Use Ab 1:800 for 20 min at RT using UltraVision Quanto Detection Systems
  * [Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.]

The optimal dilution for a specific application should be determined by the investigator.

Positive Control: Tonsil or lymph node

Cellular Localization: Cell Membrane

Storage and Stability:
Ab with sodium azide is stable for 24 months when stored at 2-8°C. Antibody WITHOUT sodium azide is stable for 36 months when stored at below 0°C.

Supplied As:
100μg/ml antibody purified from the ascites fluid by Protein A chromatography. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide. Also available without BSA and azide at 1mg/ml, or Prediluted antibody which is ready-to-use for staining of formalin-fixed, paraffin-embedded tissues.

Key References:

Limitations and Warranty:
Our products are intended FOR RESEARCH USE ONLY and are not approved for clinical diagnosis, drug use or therapeutic procedures. No products are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our data sheets and website. Our warranty is limited to the actual price paid for the product. Lab Vision is not liable for any property damage, personal injury, time or effort or economic loss caused by our products.

Material Safety Data:
This product is not licensed or approved for administration to humans or to animals other than the experimental animals. Standard Laboratory Practices should be followed when handling this material. The chemical, physical, and toxicological properties of this material have not been thoroughly investigated. Appropriate measures should be taken to avoid skin and eye contact, inhalation, and ingestion. The material contains 0.1% sodium azide as a preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material as indicated above. The National Institute of Occupational Safety and Health has issued a bulletin citing the potential explosion hazard due to the reaction of sodium azide with copper, lead, brass, or solder in the plumbing systems. Sodium azide forms hydrazoic acid in acidic conditions and should be discarded in a large volume of running water to avoid deposits forming in metal drainage pipes.
CD45RO (T-Cell Marker) Ab-1 (Clone UCHL-1)
Mouse Monoclonal Antibody
Cat. #MS-112-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 100µg/ml) (Purified Ab with BSA and Azide)
Cat. #MS-112-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)
Cat. #MS-112-R7 (7.0ml) (Ready-to-Use for Immunohistochemistry)
Cat. #MS-112-RQ (12.0ml) (Ready-to-use for Immunohistochemistry)
Cat. #MS-112-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective December 6, 2011

Additional Key References:
10. Arai E; Su WP; Roche PC; Li CY. Cutaneous histiocytic malignancy. Immunohistochemical re-examination of cases previously diagnosed as cutaneous "histiocytic lymphoma" and "malignant histiocytosis". Journal of Cutaneous Pathology, 1993, 20(2):115-20.
15. Furhita M; Ohtsuki Y; Sonobe H; Araki K; Ogata T; Toki T; Ogoshi S; Tamiya T. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku Journal of Experimental Medicine, 1993, 169(3):187-95.
17. Hayden DW; Waters DJ; Burke BA; Manivel JC. Disseminated malignant histiocytosis in a golden retriever: clinicopathologic, ultrastructural, and immunohistochemical findings. Veterinary Pathology, 1993, 30(3):256-64.
20. Kanavaros P; Mikol J; Nemeth J; Galian A; Vaunazie J; Morinet F; Ghyka G; Ursaciuc C; Ardeleanu C; Halalau F; Coman G. Tumoral infiltrate after local treatment with interferon in squamous cell carcinoma. Romanian Journal of Internal Medicine, 1993, 31(3):207-12.
28. Hayden DW; Waters DJ; Burke BA; Manivel JC. Disseminated malignant histiocytosis in a golden retriever: clinicopathologic, ultrastructural, and immunohistochemical findings. Veterinary Pathology, 1993, 30(3):256-64.
31. Kanavaros P; Mikol J; Nemeth J; Galian A; Vaunazie J; Morinet F; Ghyka G; Ursaciuc C; Ardeleanu C; Halalau F; Coman G. Tumoral infiltrate after local treatment with interferon in squamous cell carcinoma. Romanian Journal of Internal Medicine, 1993, 31(3):207-12.
32. Arai E; Su WP; Roche PC; Li CY. Cutaneous histiocytic malignancy. Immunohistochemical re-examination of cases previously diagnosed as cutaneous "histiocytic lymphoma" and "malignant histiocytosis". Journal of Cutaneous Pathology, 1993, 20(2):115-20.
37. Furhita M; Ohtsuki Y; Sonobe H; Araki K; Ogata T; Toki T; Ogoshi S; Tamiya T. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku Journal of Experimental Medicine, 1993, 169(3):187-95.
29. Chadburn A; Husain S; Knowles DM. Monoclonal antibody OPD4 detects neoplastic T cells but does not distinguish between CD4 and CD8 neoplastic T cells in paraffin tissue sections. Human Pathology, 1992, 23(8):940-7.
30. Clayton F; Reka S; Cronin WJ; Torlakovic E; Sigal SH; Kotter DP. Rectal mucosal pathology varies with human immunodeficiency virus antigen content and disease stage. Gastroenterology, 1992, 103(3):919-33.
35. Milei J; Storino R; Fernandez Alonso G; Beigelman R; Vanzulli S; Ferrans VJ. Endomyocardial biopsies in chronic chagasic cardiomyopathy. Immunohistochemical and ultrastructural findings. Cardiology, 1992, 80:424-37.
41. Travis WD; Fox CH; Devaney KO; Weiss LM; O'Leary TJ; Ogniben FP; Suffredini AF; Rosen MJ; Cohen MB; Shehlamer J. Lymphoid pneumonitis in 50 adult patients infected with the human immunodeficiency virus: lymphocytic interstitial pneumonitis versus nonspecific interstitial pneumonitis. Human Pathology, 1992, 23:529-41.
42. van der Wal AC; Becker AE; Elbers JR; Das PK. An immunocytochemical analysis of rapidly progressive atherosclerosis in human vein grafts. European Journal of Cardio-Thoracic Surgery, 1992, 6(9):469-73; discussion 474.
43. Werner M; Kaloutsis V; Walter K; Buhr T; Bernhards J; Georgii A. Immunohistochemical examination of routinely processed bone marrow biopsies. Pathology, Research and Practice, 1992, 189(6):707-13.
45. Arbusini E; Grasso M; Diegoli M; Bramore M; Foglieni AS; Albertino M; Martinelli L; Gavazzi A; Goggi C; Campana C; et al. Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical
CD45RO (T-Cell Marker) Ab-1 (Clone UCHL-1)
Mouse Monoclonal Antibody
Cat. #MS-112-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 100 µg/ml) (Purified Ab with BSA and Azide)
Cat. #MS-112-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Ready-to-use for Immunohistochemistry)
Cat. #MS-112-RQ (12.0ml) (Ready-to-use for Immunohistochemistry)
Cat. #MS-112-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective December 6, 2011

46. Berti E; Aversa GG; Soligo D; Cattoretti G; Delia D; Aiello A; Parravincini C; Hall BM; Caputo R. A6—a new 45RO monoclonal antibody for immunostaining of paraffin-embedded tissues. American Journal of Clinical Pathology, 1991, 95(2):188-93.
50. Cillari E; Milano S; Dieli M; Maltese E; Di Rosa S; Mansueto S; Salerno A; Liew FY. Reduction in the number of cell cycle. Cellular Immunology, 1991, 138(1):197-206.
51. DePalma L; Duncan B; Chan MM; Luban NL. The neonatal immune response to washed and irradiated red cells: lack of evidence of lymphocyte activation. Transfusion, 1991, 31(8):737-42.
52. DePalma L; Duncan B; Chan MM; Luban NL. The neonatal immune response to washed and irradiated red cells: lack of evidence of lymphocyte activation. Transfusion, 1991, 31(8):737-42.
58. Pelstring RJ; Allred DC; Esther RJ; Lampkin SR; Banks PM. Differential antigen preservation during tissue autolysis. Human Pathology, 1991, 22(3):237-41.
62. Takeshita M; Muller H; Mix D; Stutte HJ; Schmitts HL. Immuno- and enzymehistochemical characterization of 'plasmacytoid T-cells' in formalin-fixed paraffin-embedded tissue of reactive lymph nodes. Pathology, Research and Practice, 1991, 187(7):848-55.
64. Taubenberger JK; Cole DE; Raffeld M; Poplack DG; Jaffe ES; Medeiros LJ. Immunophenotypic analysis of acute lymphoblastic leukemia using routinely processed bone marrow specimens. Archives of Pathology and Laboratory Medicine, 1991, 115:338-42.
CD45RO (T-Cell Marker) Ab-1 (Clone UCHL-1)

Mouse Monoclonal Antibody

Cat. #MS-112-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 100µg/ml) (Purified Ab with BSA and Azide)
Cat. #MS-112-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)
Cat. #MS-112-R7 (7.0ml) (Ready-to-Use for Immunohistochemistry)
Cat. #MS-112-RQ (12.0ml) (Ready-to-use for Immunohistochemistry)
Cat. #MS-112-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective December 6, 2011